On Friday the 5th November Cambridge MP Daniel Zeichner visited Panakeia to learn more about the PANProfiler breast cancer test, a groundbreaking technological advancement set to radically accelerate diagnosis and treatment for patients, and which has recently received UKCA and CE certification for clinical use in the UK and EU.

The PANProfiler test analyses digital images of breast tumour samples to predict whether a cancer contains ER or PR receptors and therefore guide patients to the most effective treatment. The test provides a diagnostic readout from the original digital image in less than 15 minutes, with accuracy comparable to existing testing. This will therefore remove the need for expensive and time-consuming laboratory testing, bettering patient diagnosis, treatment and outcomes.

Mr Zeichner met with CEO and co-founder Dr Pahini Pandya and the team to congratulate them on receiving UKCA and CE certification before receiving a test demonstration. He said: “despite huge progress, breast cancer remains one of the biggest health challenges facing this country, and for each of the six years that I have been an MP, we have lost around 11,500 women a year to this menace. That is 11,500 mothers, daughters, sisters and friends. The PANProfiler test will be truly game changing in our fight against this deeply cruel and pernicious disease, and Dr Pandya and the Panakeia team deserve our utmost thanks and appreciation. What they are doing will dramatically speed up access to treatment and, ultimately, save countless lives.” 

Speaking ahead of the visit, Panakeia CEO and co-founder Dr Pahini Pandya said: “it is our pleasure to welcome Daniel, and we are delighted for the opportunity to demonstrate the potential for impact that Panakeia’s technology has for supporting the NHS as well as improving patient experience and outcomes.”